Have You Heard
The Obesity Health Alliance (OHA) has announced three key actions that it wants the Government to implement in its forthcoming Childhood Obesity Strategy. The announcement comes as concern mounts over delays in publishing the Government’s Childhood Obesity Strategy.
Ezetimibe (Ezetrol®), which is used to treat hypercholesterolaemia in combination with a statin, has been granted a new indication by the Medicines and Healthcare products Regulatory Agency (MHRA). The drug is now also indicated to reduce the risk of cardiovascular events in patients with coronary heart disease and a history of acute coronary syndrome when added to ongoing statin therapy or started with a statin.
NICEs recent decision not to approve Sanofis’ lipid-lowering drug alirocumab (Praulent) has been challenged in the light of the approval of evolocumab (Repatha, Amgen) for a limited number of NHS patients who are considered to be statin-intolerant. HEART UK has questioned why NICE did not seek the expertise of lipidologists during its latest review of PCSK9 inhibitors.